InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Fierce Pharma

After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
TipRanks on MSN

InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
Nasdaq

InflaRx Reports Efficacy Signals In Terminated Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum

(RTTNews) - InflaRx N.V. (IFRX) today released detailed analyses from its terminated Phase 3 trial of Vilobelimab in pyoderma gangrenosum. The study was stopped in May 2025 after an Independent Data ...
The Pharma Letter

InflaRx claims 'signals of efficacy' from analyses of terminated vilobelimab trial

German drug developer InflaRx, which is developing anti-inflammatory therapeutics by targeting the complement system, has ...
Nature

An Enzyme from Bacteria able to Destroy Penicillin

FLEMING 1 noted that the growth of B. coli and a number of other bacteria belonging to the colityphoid group was not inhibited by penicillin. This observation has been confirmed. Further work has been ...